Warning Letter

News
Article

FDA cites Essential Pharmacy Compounding (Omaha) for bulk-compounding of verterinary drugs.

In a 7 January warning letter (), the US Food and Drug Administration's Kansas City district office (Lenexa, KS) cited Omaha's Essential Pharmacy Compounding for mass-producing veterinary drugs from bulk active pharmaceutical ingredients.

The warning cited large-scale compounding of altrenogest, amikacin sulfate, dipyrone, flunixin belumine, ketoprofen, ivermectin, ompeprazole, phenylbutazone, and tripelemine hydrochoride, "among many others." As is typical in these warnings, the agency voiced concerns that Essential is compounding not for individual patients but for third-party resale, and that the compounded drugs duplicate approved products in dosage and concentration.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content
Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

CordenPharma and Viking Therapeutics to Partner for Integrated Supply of GLP-1s

Patrick Lavery
March 13th 2025
Article

The multi-year strategic partnership is intended to support commercial demand of Viking Therapeutics’ GLP-1 candidate, VK2735.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

New Almac Pharma Services Commercial Manufacturing Facility Opens in Northern Ireland

Patrick Lavery
March 11th 2025
Article

The company’s 100,000-sq.-ft. space is expected to enhance its capabilities for commercial oral dose treatment manufacturing in a variety of therapeutic areas.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Noramco Group Establishes Sterile Injectable Manufacturing Capabilities with $25 Million Investment

Patrick Lavery
March 10th 2025
Article

The investment is intended for the Halo Pharma facility in Whippany, NJ, and aims to help relieve capacity shortages in the injectable supply chain in the United States.

research, doctor, microscope, experiment, dx, digital transformation, data, analysis, science, researcher, graph, chart, pharmaceutical, pharmacy, medicine, information, development, research institute | Image Credit: ©metamorworks - stock.adobe.com

Full Tolerance Coverage Method for Assessing Uniformity of Dosage Units with Large Sample Sizes

Pramote Cholayudth
March 10th 2025
Article

The ‘full tolerance coverage method’ is introduced as a coverage estimation approach for assessing the uniformity of dosage units from large sample sizes, ensuring that no dosage unit exceeds the specification range.